| miR-181a directly inhibits the expression of thyroid hormone receptor beta (THRB), an important tumor suppressor gene, and inhibits thyroid hormone-THRB pathway | thyroid, |
| miR-181a may function as an oral squamous cell carcinoma suppressor by targeting on K-ras oncogene. | oral |
| miR-181b may function as a tumor suppressor in gastric adenocarcinoma cells through negative regulation of CREB1 | gastric, |
| our results indicate that miR-181a might act as a tumor suppressor in gastric cancer. | gastric, |
| miR-181a could act as a tumor suppressor in pediatric ALL with over expression of its target pair, Smad7. | pediatric, |
| These findings indicate that miR-181 functions as a tumor suppressor and plays a substantial role in inhibiting the tumorigenesis and reversing the metastasis of ovarian cancer through RTKN2-NF-kappaB signaling pathway in vitro | ovarian, |
| This study, we performed a comprehensive analysis of putative human miRNA oncogenes and tumor suppressors. We found that miRNA oncogenes and tumor suppressors clearly show different patterns in function, evolutionary rate, expression, chromosome distribution, molecule size, free energy, transcription factors, and targets. | None |
| MiR-181a-5p acts as an antioncogenic gene, which has been identified as a dual function miRNA involved in tumorigenesis in various cancer cell lines. | None |
| Proliferation and apoptosis assays demonstrated that miR-181a/135a/302c function as tumor suppressors via repressing PLAG1/IGF2 signaling. | None |
| Inhibition of protooncogenic microRNA-181a may suppress proliferation and invasion and promote apoptosis of cervical cancer cells through the PTEN/Akt/FOXO1 pathway. | cervical, |
| miR-181a plays an oncogenic role in thyroid cancer; by targeting RB1, it promotes cell cycle progression and inhibits apoptosis. | thyroid, |